← Back to all signals
RESEARCH PAPER ANALYSIS

Non-Pharmacological interventions for managing fatigue in parkinson's disease: A systematic review and meta-analysis.

Systematic review/meta-analysis of five RCTs (n=270) found exercise interventions reduced fatigue in Parkinson’s disease (SMD −1.34) but with substantial heterogeneity and low certainty, while acupuncture showed no benefit.

PMID41908103
JournalClinical parkinsonism & related disorders
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Systematic review/meta-analysis of five RCTs (n=270) found exercise interventions reduced fatigue in Parkinson’s disease (SMD −1.34) but with substantial heterogeneity and low certainty, while acupuncture showed no benefit.

WHY IT MATTERS

Research significance

The paper highlights exercise as a potentially useful symptomatic, non‑pharmacological strategy and pinpoints methodological gaps (small, heterogeneous trials, lack of PD‑specific fatigue measures) that should guide future mechanistic and sufficiently powered clinical studies, but it offers limited…

ABSTRACT

Source abstract

BACKGROUND: Fatigue is a prevalent and disabling non-motor symptom in Parkinson's disease (PD), yet evidence for effective management strategies, particularly non-pharmacological approaches, remains limited. OBJECTIVE: To systematically review and meta-analyse the efficacy of non-pharmacological interventions aimed at reducing fatigue in people with PD (PwP). METHODS: MEDLINE, CINAHL and AMED were searched from inception to January 2026 for randomised controlled trials (RCTs) in which fatigue was a primary outcome. Risk of bias was assessed using the Cochrane RoB2 tool. Standardised mean differences (SMDs) were pooled using random-effects models, and certainty of evidence was assessed using GRADE. The protocol was registered with PROSPERO (CRD42023394180). RESULTS: Five RCTs (n = 270 participants) met the inclusion criteria, evaluating exercise-based interventions (3 trials, n = 142) and acupuncture (2 trials, n = 128). Exercise interventions were associated with a statistically significant reduction in fatigue compared with controls (SMD =  - 1.34, 95% CI - 2.24 to - 0.44, p = 0.003), although heterogeneity was substantial (I2 = 89%). Acupuncture showed no significant effect compared with sham (SMD = 0.17, 95% CI - 0.13 to 0.51, p = 0.26), with low heterogeneity (I2 = 0%). Risk of bias was low in the acupuncture trials but rated as 'some concerns' for all exercise trials. GRADE assessment indicated low certainty evidence for exercise and moderate certainty evidence for acupuncture. Secondary outcomes such as quality of life and sleep were inconsistently reported and showed minimal change. CONCLUSIONS: Exercise-based interventions show preliminary promise for reducing fatigue severity in PwP, but the evidence is limited by heterogeneity and methodological concerns. Acupuncture appears ineffective compared to sham. High-quality, adequately powered RCTs evaluating diverse non-pharmacological approaches, including psychological and self-management strategies, are urgently needed, using standardised PD-specific fatigue measures.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic